Literature DB >> 19351815

MicroRNA signature of primary pigmented nodular adrenocortical disease: clinical correlations and regulation of Wnt signaling.

Dimitrios Iliopoulos1, Eirini I Bimpaki, Maria Nesterova, Constantine A Stratakis.   

Abstract

MicroRNAs comprise a novel group of gene regulators implicated in the development of different types of cancer; however, their role in primary pigmented nodular adrenocortical disease (PPNAD) has not been investigated. PPNAD is a bilateral adrenal hyperplasia often associated with Carney complex, a multiple neoplasia syndrome; both disorders are caused by protein kinase A (PKA) regulatory subunit type 1A (PRKARIA)-inactivating mutations. We identified a 44-microRNA gene signature of PPNAD after comparing PPNAD with normal adrenal samples. Specifically, 33 microRNAs were up-regulated and 11 down-regulated in PPNAD relative to normal tissues. These results were validated by stem loop real-time PCR analysis. Comparison of microRNA microarray data with clinicopathologic variables revealed a negative correlation (r = -0.9499) between let-7b expression and cortisol levels in patients with PPNAD. Integration of microRNA microarray with serial analysis of gene expression data together with bioinformatic algorithm predictions revealed nine microRNA-gene target pairs with a potential role in adrenal pathogenesis. Using a PPNAD cell line, we showed that miR-449 was up-regulated and identified its direct target, WNT1-inducible signaling pathway protein 2 (WISP2); in addition, pharmacologic inhibition of PKA resulted in the up-regulation of miR-449 leading to the suppression of WISP2. Overall, we investigated, for the first time, the microRNA profile and its clinical significance in PPNAD; these data also suggest that PKA, via microRNA regulation, affects the Wnt signaling pathway, which through expression and clinical studies is suspected to be a primary mediator of PRKAR1A-related tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351815      PMCID: PMC3124768          DOI: 10.1158/0008-5472.CAN-09-0155

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  An immortalized human cell line bearing a PRKAR1A-inactivating mutation: effects of overexpression of the wild-type Allele and other protein kinase A subunits.

Authors:  Maria Nesterova; Ioannis Bossis; Feng Wen; Anelia Horvath; Ludmila Matyakhina; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2007-12-04       Impact factor: 5.958

2.  Using expression profiling data to identify human microRNA targets.

Authors:  Jim C Huang; Tomas Babak; Timothy W Corson; Gordon Chua; Sofia Khan; Brenda L Gallie; Timothy R Hughes; Benjamin J Blencowe; Brendan J Frey; Quaid D Morris
Journal:  Nat Methods       Date:  2007-11-18       Impact factor: 28.547

3.  MicroRNA expression profiles in serous ovarian carcinoma.

Authors:  Eun Ji Nam; Heejei Yoon; Sang Wun Kim; Hoguen Kim; Young Tae Kim; Jae Hoon Kim; Jae Wook Kim; Sunghoon Kim
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

4.  Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.

Authors:  L S Kirschner; J A Carney; S D Pack; S E Taymans; C Giatzakis; Y S Cho; Y S Cho-Chung; C A Stratakis
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

5.  Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer.

Authors:  Stefan Ambs; Robyn L Prueitt; Ming Yi; Robert S Hudson; Tiffany M Howe; Fabio Petrocca; Tiffany A Wallace; Chang-Gong Liu; Stefano Volinia; George A Calin; Harris G Yfantis; Robert M Stephens; Carlo M Croce
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 6.  Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome).

Authors:  Constantine A Stratakis
Journal:  Endocr Dev       Date:  2008

7.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.

Authors:  Philip A Gregory; Andrew G Bert; Emily L Paterson; Simon C Barry; Anna Tsykin; Gelareh Farshid; Mathew A Vadas; Yeesim Khew-Goodall; Gregory J Goodall
Journal:  Nat Cell Biol       Date:  2008-03-30       Impact factor: 28.824

8.  The let-7 microRNA represses cell proliferation pathways in human cells.

Authors:  Charles D Johnson; Aurora Esquela-Kerscher; Giovanni Stefani; Mike Byrom; Kevin Kelnar; Dmitriy Ovcharenko; Mike Wilson; Xiaowei Wang; Jeffrey Shelton; Jaclyn Shingara; Lena Chin; David Brown; Frank J Slack
Journal:  Cancer Res       Date:  2007-08-15       Impact factor: 12.701

Review 9.  New genes and/or molecular pathways associated with adrenal hyperplasias and related adrenocortical tumors.

Authors:  Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2008-11-21       Impact factor: 4.102

10.  MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype.

Authors:  Cherie Blenkiron; Leonard D Goldstein; Natalie P Thorne; Inmaculada Spiteri; Suet-Feung Chin; Mark J Dunning; Nuno L Barbosa-Morais; Andrew E Teschendorff; Andrew R Green; Ian O Ellis; Simon Tavaré; Carlos Caldas; Eric A Miska
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  35 in total

1.  MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML.

Authors:  Sukanya Suresh; Lynn McCallum; Wanhua Lu; Noureddine Lazar; Bernard Perbal; Alexandra E Irvine
Journal:  J Cell Commun Signal       Date:  2011-06-03       Impact factor: 5.782

2.  CCN5: biology and pathophysiology.

Authors:  Joshua W Russo; John J Castellot
Journal:  J Cell Commun Signal       Date:  2010-09-21       Impact factor: 5.782

3.  Adrenal cortex and micro-RNAs: An update.

Authors:  Fabio Rueda Faucz; Constantine A Stratakis
Journal:  Cell Cycle       Date:  2010-10-13       Impact factor: 4.534

4.  Epigenetic regulation of WNT signaling in chronic lymphocytic leukemia.

Authors:  Lynda B Bennett; Kristen H Taylor; Gerald L Arthur; Farahnaz B Rahmatpanah; Sam I Hooshmand; Charles W Caldwell
Journal:  Epigenomics       Date:  2010-02-01       Impact factor: 4.778

5.  Temporal changes of microRNA gga-let-7b and gga-let-7i expression in chickens challenged with subgroup J avian leukosis virus.

Authors:  Jun Ji; Huiqin Shang; Huanmin Zhang; Hongxin Li; Jingyun Ma; Yingzuo Bi; Qingmei Xie
Journal:  Vet Res Commun       Date:  2017-02-11       Impact factor: 2.459

Review 6.  The cAMP pathway and the control of adrenocortical development and growth.

Authors:  Cyrille de Joussineau; Isabelle Sahut-Barnola; Isaac Levy; Emmanouil Saloustros; Pierre Val; Constantine A Stratakis; Antoine Martinez
Journal:  Mol Cell Endocrinol       Date:  2011-10-15       Impact factor: 4.102

Review 7.  microRNA regulation of Wnt signaling pathways in development and disease.

Authors:  Jia L Song; Priya Nigam; Senel S Tektas; Erica Selva
Journal:  Cell Signal       Date:  2015-04-02       Impact factor: 4.315

8.  Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling.

Authors:  Madson Q Almeida; Michael Muchow; Sosipatros Boikos; Andrew J Bauer; Kurt J Griffin; Kit Man Tsang; Chris Cheadle; Tonya Watkins; Feng Wen; Matthew F Starost; Ioannis Bossis; Maria Nesterova; Constantine A Stratakis
Journal:  Hum Mol Genet       Date:  2010-01-15       Impact factor: 6.150

9.  miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A.

Authors:  Xiaojing Yang; Min Feng; Xia Jiang; Zhenlong Wu; Zhimei Li; Meiyee Aau; Qiang Yu
Journal:  Genes Dev       Date:  2009-10-15       Impact factor: 11.361

Review 10.  cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse.

Authors:  Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2013-02-26       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.